Last reviewed · How we verify
Syntocinon 24 IU
Syntocinon 24 IU, marketed by University Hospital Freiburg, is an established drug with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing use. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Syntocinon 24 IU |
|---|---|
| Sponsor | University Hospital Freiburg |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Understanding Cognition, Oxytocin & Pain in Elders (PHASE2, PHASE3)
- Oxytocin's Effects on Emotional Processing and Its Acting Routes (NA)
- Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain (PHASE2, PHASE3)
- The Power of Belief: Expectation-driven and Placebo Modulation of Empathic Pain (NA)
- Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus (PHASE2)
- Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome (PHASE2, PHASE3)
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Syntocinon 24 IU CI brief — competitive landscape report
- Syntocinon 24 IU updates RSS · CI watch RSS
- University Hospital Freiburg portfolio CI